TLSA Projected Dividend Yield
Ord/Tiziana Life Sciences Ltd ( NASDAQ : TLSA )Tiziana Life Sciences is a biotechnology company that is focused on the discovery and development of molecules to treat unmet medical needs in oncology and immunology. Co.'s main product candidate in immunology is Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody (mAb) in clinical development. MAbs represent a single pure antibody produced by single clones and are a class of human therapeutics for treating cancers and autoimmune diseases. Co.'s main product candidate in oncology is Milciclib (TZLS-201), which is an orally bioavailable, small molecule spectrum inhibitor of cyclin-dependent kinases, and Src family kinases. 20 YEAR PERFORMANCE RESULTS |
TLSA Dividend History Detail TLSA Dividend News TLSA Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |